FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 554 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Cancer in My Community: Encouraging Cancer Screening in Estonia May 23, 2023 The Nobel Prize in Chemistry 2020 was Awarded “for the Development... October 12, 2020 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan July 21, 2022 New on NCI’s Websites for August 2024 August 16, 2024 Load more HOT NEWS Vulnerability in Brain Tumors May Open Door to New Treatments Starving cancer into submission Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
